NCT02997761 2026-04-07
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
University of California, Davis
Phase 2 Completed
Clinical Trials
7 trialsNCT06649006 2026-01-08
Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
Amgen
Phase 1 Completed
NCT02568553 2025-11-26
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT03160079 2025-11-10
Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts
University of California, San Diego
Phase 1/2 Completed
NCT03480438 2025-10-03
EWALL-BOLD
Goethe University
Phase 2 Completed
NCT02458014 2025-09-23
Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04827745 2025-07-03
Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL
University of Maryland, Baltimore
Phase 2 Completed